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Abstract
Nonsteroidal anti-inflammatory drug-activated gene-1 (NAG-1) is induced by nonsteroidal anti-inflammatory drugs and
possesses proapoptotic and antitumorigenic activities. Although tolfenamic acid (TA) induces apoptosis in head and neck
cancer cells, the relationship between NAG-1 and TA has not been determined. This study investigated the induction of
apoptosis in head and neck cancer cells treated by TA and the role of NAG-1 expression in this induction. TA reduced head
and neck cancer cell viability in a dose-dependent manner and induced apoptosis. The induced apoptosis was coincident
with the expression of NAG-1. Overexpression of NAG-1 enhanced the apoptotic effect of TA, whereas suppression of NAG-1
expression by small interfering RNA attenuated TA-induced apoptosis. TA significantly inhibited tumor formation as
assessed by xenograft models, and this result accompanied the induction of apoptotic cells and NAG-1 expression in tumor
tissue samples. Taken together, these results demonstrate that TA induces apoptosis via NAG-1 expression in head and neck
squamous cell carcinoma, providing an additional mechanistic explanation for the apoptotic activity of TA.
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Introduction
With over 500,000 cases worldwide and a high mortality rate,
head and neck squamous cell carcinoma (HNSCC) is the sixth
most common cancer in men. Even with improved treatments, the
overall survival rate has been under 50% for the past 30 years [1].
Although some patients achieve long-term survival, particularly
those diagnosed with early-stage disease, most patients with this
type of cancer have advanced disease at the time of diagnosis.
These patients run a risk of recurrent disease, distant metastases,
or second primary tumors, and have a median survival of only 6–8
months [2]
The 5-year overall survival rate for patients with advanced
HNSCC is around 30%, which is essentially unchanged from the
rate recorded two decades ago in spite of various treatment trials.
Therefore, preventive strategies are desirable, and much research
is currently devoted to chemoprevention that aims to prevent
HNSCC progression at an early stage. However, which chemo-
preventive agents are the safest and most effective against HNSCC
remains unclear. It is of clinical importance to investigate the
efficacy of nonsteroidal anti-inflammatory drugs (NSAIDs) as
chemopreventive agents.
Chemopreventive agents play an important role in interrupting
the carcinogenic process and inhibiting the recurrence of
precancerous lesions. At present, the pharmaceutical agents that
have been most widely investigated as chemopreventive agents are
NSAIDs. NSAIDs have been clinically used as chemopreventive
agents for familial adenomatous polyposis, with the mode of action
being the inhibition of cyclooxygenase-2 (COX-2) [3,4]. However,
chemopreventive and antitumorigenic activities of NSAIDs have
also been observed in COX-2-deficient cells, indicating that
NSAIDs also exert their anticancer effect through a mechanism
other than COX-2 suppression. One such mechanism involves the
induction of NSAID-activated gene-1 (NAG-1) [5].
NAG-1 was identified from indomethacin (a COX inhibitor)-
induced gene library [5]. NAG-1 is a member of the transforming
growth factor-beta (TGF-b) superfamily and is also known as
macrophage inhibitory cytokine-1 (MIC-1), growth differentiation
factor 15 (GDF15), and prostate derived factor (PDF) [6,7,8].
Purified recombinant NAG-1 is able to inhibit lipopolysaccharide-
induced tumor necrosis factor-alpha (TNF-a) production in
macrophages, suggesting that NAG-1 acts as an autocrine
regulatory molecule [9]. In vitro and in vivo, NAG-1 has anti-
tumorigenic and pro-apoptotic activities independent of COX
inhibition [5,10]. NSAIDs and several antitumorigenic com-
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genistein, catechins, and peroxisome proliferator-activated recep-
tor-c ligands, regulate NAG-1 expression in a prostaglandin-
independent manner [11,12,13,14,15].
However, until now, the relationship, if any, between NAG-1
and TA in HNSCC has not been investigated. Pro-apoptotic
activity of NAG-1 may provide a molecular basis to explain
chemopreventive agent, TA-mediated antitumorigenesis.
In this study, we examined the regulation of NAG-1 expression
during TA-induced apoptosis in HNSCC cells. NAG-1 small
interfering RNA (siRNA)-mediated inhibition of NAG-1 expres-
sion attenuated TA-induced apoptosis. Furthermore, the in vivo
antitumorigenic activity of TA in mice was investigated to evaluate
the use of TA as a chemopreventive agent in HNSCC. The data
suggest that the induction of NAG-1 may provide a novel
mechanism for understanding the downstream effectors for TA-
induced apoptosis in HNSCC.
Materials and Methods
Cell lines and reagents
Four established human head and neck cancer cell lines – KB
(an oral cancer cell line), SCCQLL1 (an oral cancer cell line), HN3
(a laryngeal cancer cell line), and FaDu (a hypopharyngeal cancer
cell line) – were obtained from American Type Culture Collection
(Manassas, VA) and Korean Cell Line Bank (Seoul, Korea). The
cells were grown in Dulbecco’s modified Eagle’s medium with
10% fetal bovine serum and penicillin-streptomycin at 100 U/ml
(GIBCO, Carlsbad, CA) at 37uC in a humidified atmosphere with
5% CO2 and 95% air. TA, diclofenac, sulindac sulfide,
indomethacin, and piroxicam (Sigma-Aldrich, St. Louis, MO)
were dissolved in autoclaved water as stock solution for in vitro
studies. For investigate the effect of TA on normal cells, we used
HaCaT cells (normal keratinocytes) that were obtained from
Korean Cell Line Bank (Seoul, Korea).
Cell proliferation assay
Cell viability was tested using an assay based on the conversion
of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide
(MTT; Sigma Aldrich). MTT solution was added to 40 ml of cell
suspension for 4 h. After three washes with phosphate buffered
saline (PBS, pH 7.4), the insoluble formazan product was dissolved
in 100 ml of dimethylsulfoxide. Optical density (OD) was measured
for each culture well using a microplate reader (Bio-Tek,
Winooski, VT) at 540 nm. The OD of control cells were taken
as 100% viability.
Terminal deoxynucleotidyl transferase-mediated dutp-
biotin nick end labeling (tunel) assay
DNA fragmentation was analyzed with the in situ cell death
detection kit (Roche Molecular Biochemicals, Basel, Switzerland),
according to the instructions of the manufacturer. The stained cells
were analyzed under a fluorescence microscope (Carl Zeiss,
Oberkochen, Germany).
Flow cytometry detection of apoptosis
Apoptosis was detected using the Annexin V-fluorescein
isothiocynate (FITC) apoptosis detection kit (BD Biosciences,
Bedford, MA). Briefly, cells were plated in 6-well culture dishes
and incubated with 0, 10, 20, and 40 mM TA for 24 h. The cells
were harvested, washed with PBS, and stained with Annexin V-
FITC and propidium iodide (PI). Early and late apoptosis were
quantified according to the manufacturer’s instructions. Apoptosis
was detected using a FACS Canto system (BD Biosciences,
Bedford, MA), with excitation and emission settings of 488 and
530 nm, respectively.
Mitochondrial membrane potential (MMP) assay
MMP of intact cells was measured by flow cytometry with the
lipophilic cationic probe 5,5 V,6,6 V-tetrachloro-1,1 V 3,3 V-tetra
ethylbenzimidazolcarbocyanine iodide (JC-1; Molecular Probes,
Eugene, OR). The culture medium was briefly removed from the
adherent KB cells, and the cells were rinsed with PBS. Cell
monolayers were incubated with DMEM and 5 mg/ml JC-1 at
33uC for 20 min. The cells were subsequently washed twice with
cold PBS and trypsinized. Cell pellets were then resuspended in
500 ml PBS. The change in MMP was measured by flow
cytometry (BD Biosciences) and fluorescence microscopy at 72 h
after irradiation.
Transfectiom of NAG-1 cDNA and RNA interference (rnai)
All transfection experiments were performed using Lipofecta-
mine 2000 reagent (Invitrogen, Carlsbad, CA) according to the
manufacturer’s instructions, as described previously [5]. After
incubation for 24 h, the medium was removed and the cells were
washed with PBS and treated with either TA or vehicle for 24 h.
NAG-1 cDNA was previously described [5]. siRNA for control
and NAG-1(sense CUCAGUUGUCCUGCCCUGUdTdT and
antisense ACAGGGCAGGACAACUGAGdTdT) were pur-
chased from Invitrogen.
Western blot analysis
Cells were washed with cold PBS and suspended in RIPA buffer
(Sigma-Aldrich) supplemented with PhosSTOP and Complete
Mini EDTA-free (Roche Molecular Biochemicals, Basel, Switzer-
land). The proteins from KB cells were electrotransferred to
Immobilon-P membranes (Millipore, Bedford, MA). Detection of
specific proteins was carried out with an enhanced chemilumi-
nescence Western blotting kit according to the manufacturer’s
instructions.
Animal study
KB cells (1610
6) re-suspended in PBS were subcutaneously
administered to the lower-right flank of each BALB/c nu/nu
mouse. After 1 week, when tumors reached approximately
100 mm in diameter, the mice were randomly divided into two
groups (n=10 per group) and treatment was initiated. Treatment
was started the day after cell implantation with either intraper-
itoneal injection of TA (25 mg/kg) daily (treatment groups) or
saline alone (control group). Tumors were measured with a sliding
caliper once every 2 days and the volumes (mm
3) were calculated
according to the formula V=A6B
260.52, in which A is the
largest superficial diameter and B is the smallest superficial
diameter [16]. Animals were euthanized, and tumors were
collected and weighed 17 days after implantation. Half of the
tissue was snap-frozen in liquid nitrogen and used for protein
extraction. The other half was fixed overnight in neutral buffered
formalin and processed by routine methods. Western blotting of
NAG-1 was performed on tumor specimens and normal soft tissue
samples. This study was approved by the Committee for Ethics in
Animal Experiments of the Ajou University School of Medicine.
Statistical analyses
Where data were derived from three independent experiments,
the parameters were expressed as mean 6 SD. Comparison of the
means of different groups was made using one-way analysis of
variance. The Student-Newman-Keuls test was used for pair-wise
Tolfenamic Acid-Induced Apoptosis
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measures of ANOVA. Statistical significance was inferred at
p,0.05.
Results
Induction of NAG-1 and apoptosis in HNSCC cells by
various NSAIDs
To investigate the effects of NSAIDs on the growth of HNSCC
cells, the four selected HNSCC cell lines were incubated with
varying concentrations (0, 5, 10, 30, 50, 70, 100, 150, and
200 mM) of TA for 16 h and cell viability was measured by the
MTT assay. As shown in Fig. 1, various NSAIDs reduced cell
viability in a dose-dependent manner (Fig. 1A) and TA
significantly reduced viability of the HNSCC cell lines (Fig. 1B).
Especially, TA was the most potent inducer both apoptosis and
NAG-1 expression (Figs. 1 and 2), and was selected for further
research. Next, to investigate the toxic effects of TA on normal
cells, we performed cell proliferation assay in HaCaT cells (normal
keratinocytes). HaCaT cells were treated with TA for 16 h at the
indicated concentrations ( 0, 5, 10, 30, 50, 70, 100, 150, 200 mM).
The relative viability of the HaCaT cells was examined using the
MTT assay (Fig. 1C). TA was minimally cytotoxic on HaCaT
upto 100 mM, but TA was significant cytotoxic on the cells at the
high concentrations.
To explore the relationship between the NSAID-induced
apoptosis and NAG-1 expression, HNSCC cells were treated with
various concentrations of NSAID and protein levels of NAG-1
were measured by Western blot analysis. As shown in Fig. 2,
various NSAIDs induced the expression of NAG-1 protein in KB
cells (Fig. 2A) and TA induced expression of NAG-1 in various
HNSCC cells (Fig. 2B). TA also induced expression of NAG-1
protein in dose and time-dependent manners (Figs. 2C and 2D).
When cells were treated with 40 mM of TA for various times,
induction of NAG-1 protein was seen after 3 h in KB cells
(Fig. 2D). The same membrane was stripped and re-probed for
cleaved poly (ADP-ribose) polymerase (PARP) and cleaved
caspase-3, which were also induced by TA (Figs. 2C and 2D).
Overall, these results suggest that TA-induced apoptotic cell death
and cell growth arrest in HNSCC cell lines is probably mediated
by the expression of the pro-apoptotic protein NAG-1. To
determine whether the TA-induced cell death was by apoptosis,
we performed fluorescence-activated cell sorting (FACS) with
Annexin-V/PI staining and TUNEL assay. As shown in Fig. 3,
Annexin V-FITC-positive cells were also increased by TA
treatment in KB cells (Fig. 3A) and TUNEL-positive cells by TA
increased in a dose-dependent manner (0, 10, 20, and 40 mM) in
KB cells (Fig. 3B). MMP can be used as an index of mitochondrial
pore opening, which is an indicator of mitochondrial dysfunction.
Quantitative analysis of red and green fluorescent signals from
intracellular JC-1 dye reflects the degree of mitochondrial damage.
Therefore, we examined the effect of TA on MMP in the KB cells
to determine whether the loss of MMP could play a role in TA-
induced apoptosis. As shown in Fig. 3C, a high MMP was
maintained in control cells, as indicated by the predominantly red
fluorescence of the JC-1 dye. However, TA treatment increased
the green cell fluorescence indicating a loss of MMP and
mitochondrial damage (Fig. 3C).
Overexpression and suppression of NAG-1 promotes and
attenuates TA-induced apoptosis, respectively
Next, we attempted to clarify the significance of NAG-1 up-
regulation in TA-induced apoptosis. Human NAG-1 cDNA was
transfected into KB cells. NAG-1 overexpression caused increased
Figure 1. Effect of various NSAIDs on proliferation of various
head and neck cancer cell lines and normal keratinocytes.
Results of the proliferation assay. Cells were plated in 96-well tissue
culture plates at 1000 cells/well in a final volume of 100 ml of medium
and were allowed to attach for 2 days. The cells were then treated once
with varying doses of TA for 24 h. Cell proliferation was estimated by
the MTT assay. Values represent the mean 6 S.D. from five independent
experiments. * p,0.05; ** p,0.01, compared with the control group. (A)
The KB head and neck cancer cell line was treated with NSAIDs. (B)
Cytotoxicity of TA on various HNSCC cells. (C) Cytotoxicity of TA on
normal keratinocyte cells (HaCaT).
doi:10.1371/journal.pone.0034988.g001
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NAG-1 with 40 mM TA further enhanced both cleaved caspase-3
and cleaved PARP, compared to TA-treated control cells (Fig. 4A).
In parallel with increased caspase-3, KB/NAG-1 cells markedly
increased typical morphological features of apoptosis, including
Annexin V-positive and TUNEL-positive cell staining, compared
to control cells. This effect was further increased by TA treatment
(Fig. 4B and 4C). We then examined whether suppression of
NAG-1 expression could modulate TA-induced apoptosis. KB
cells transfected with either NAG-1 siRNA or control siRNA were
treated with or without 30 mM TA for 24 h. Immunoblot analysis
demonstrated that transfection of siRNA against NAG-1 sup-
pressed expression of NAG-1, cleaved PARP and cleaved caspase-
3 in the presence of TA, compared to control transfected cells
(Fig. 5A). Under these conditions, TA-mediated Annexin V-
positive and TUNEL-positive cells were significantly attenuated in
cells transfected with NAG-1 siRNA (Figs. 5B and 5C). Taken
together, these results suggest that NAG-1 plays a role in apoptosis
and that inhibition of NAG-1 in KB cells affect TA-induced
apoptosis. Moreover, these results suggest that TA-induced NAG-
1 up-regulation may be one of the underlying mechanisms that
contribute to TA-induced apoptosis.
Effect of TA on tumorigenicity and apoptosis in BALB/c
nu/nu mice
To determine whether the aforementioned results were evident
in vivo, we used the BALB/c nu/nu mice and randomly divided
them equally into the control group and treatment (25 mg/kg TA)
group after tumor formation (approximately 100 mm in diameter).
All mice survived throughout the experimental period. Adminis-
tration of TA significantly affected tumor formation and
development (p,0.05; Figs. 6A and 6B). However, there was no
significant difference between the two groups in body weight.
TUNEL staining revealed that TA significantly increased the
number of TUNEL positive cells (Fig. 6C). To investigate the level
of NAG-1 in the tumors, Western blotting of NAG-1 expression on
tumor specimens of BALB/c nu/nu mice was performed. Strong
induction of in vivo NAG-1 expression in proteins that were
extracted from tumors in TA-treated mice was evident, compared
to control mice. (Fig. 6D) The data suggest that TA increases the
expression of NAG-1 in tumors and that the induced NAG-1
suppresses the size of tumors.
Discussion
NSAIDs inhibit COX-dependent synthesis of prostaglandins
that mediate inflammatory responses in multiple tissues [3,4,5].
NSAIDs also induce cell growth inhibition, apoptosis, and
antiangiogenesis; activation of the pathways involved in these
effects is critical for the reported anticarcinogenic activities of
NSAIDs and related COX-2 inhibitors, such as celecoxib
[17,18,19,20,21]. Extensive epidemiologic studies of the role of
NSAIDs in the prevention and treatment of colon cancer has
provided evidence that the use of NSAIDs, such as aspirin and
some COX-2 inhibitors, is associated with a decrease in the
incidence and/or mortality of colon cancer [22,23,24].
Recently, it was reported that NSAIDs have other targets in
addition to COX-2. He et al [25]. reported that the peroxysome
proliferation activating receptor delta (PPARd) is also an
adenomatous polyposis coli (APC)-regulated target of NSAIDs.
In addition, NSAIDs metabolites can suppress the nuclear factor-
kB (NF-kB) survival signal via I kB kinase a (IkKa) inhibition [26].
These suggest that NSAIDs inhibit tumor growth via COX-
dependent and -independent pathways.
TA is a potent, well-tolerated NSAID with a low gastric side
effect and high therapeutic index, as compared with other
NSAIDs [27]. It possesses antipyretic and analgesic activities as
evidenced in several animal models and has shown promising
results in long-term treatment of osteoarthritis, rheumatoid
arthritis, and migraine [27]. TA also affects apoptosis in colorectal
cancer cells, as well as metastasis and tumorigenesis in pancreatic
cancer models [28] [29,30].
Specificity protein 1 (Sp1) degradation by TA inhibits several
cancer cell lines including pancreatic cancer cells [28,29]. Thus,
Sp1 can be another possible molecular target for TA-induced
Figure 2. Induction of NAG-1 expression in head and neck cancer cell lines by various NSAIDs. (A) NAG-1 expression was induced by
NSAIDs in the following order: TA, indomethacin, sulindac sulfide, diclofenac, and piroxicam. Expression of NAG-1 was measured by Western blot
analysis and normalized to the level of a-tubulin expression. (B) Induction of NAG-1 expression in various head and neck cancer cell lines by TA. (C and
D) TA dose- and time-dependently increases NAG-1 protein levels in KB cells. KB cells were treated with 0, 10, 30, and 40 mM TA for 24 h. Expression of
NAG-1 was measured by Western blot analysis and a–tubulin was used as loading control. The same membrane was stripped and re-probed with
cleaved PARP and cleaved caspase-3 antibody.
doi:10.1371/journal.pone.0034988.g002
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PLoS ONE | www.plosone.org 4 April 2012 | Volume 7 | Issue 4 | e34988Figure 3. Effect of TA on apoptosis and mitochondrial membrane potential in KB cells. (A) For flow cytometric detection of apoptotic
cells, cells were plated in 6-well culture dishes and incubated with 0, 10, 20, 30 and 40 mM TA for 24 h. The cells were harvested and washed with PBS
and then stained with Annexin V-FITC and propidium iodide (PI). Early and late apoptosis were quantified. Data are mean values obtained from three
independent experiments and bars represent standard deviations. (B) Results of TUNEL analysis. Apoptosis in KB cells was determined by the TUNEL
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PLoS ONE | www.plosone.org 5 April 2012 | Volume 7 | Issue 4 | e34988method using an in situ cell detection kit. Cells were treated with indicated concentrations of TA for 24 h. TUNEL staining was increased in apoptotic
cell death. Left, 49,6-diamidino-2-phenylindole (DAPI); middle, TUNEL; right, merge. The scale bar denotes 50 mm. (C) The effect of TA on the
mitochondrial apoptotic pathway. After applying 10, 20, 30, and 40 mM TA for 24 h, the JC-1 fluorescence shifted from red-orange to green,
indicating depolarization of the mitochondrial membrane potential (MMP). The MMP change was objectively measured using flow cytometry. The
data represent the mean 6 SD of three independent experiments. *, P,0.05; **, P,0.01; ***, P,0.001 compared with the control group.
doi:10.1371/journal.pone.0034988.g003
Figure 4. Effect of enhanced expression of NAG-1 on TA-induced apoptosis in KB cells. KB/NAG-1 and KB/vector cells were treated with
30 mM TA for 24 h, and apoptosis was analyzed using a TUNEL assay and by FACS with annexin V-FITC/PI. (A) Western Blot. Equal amounts of cell
lysates (30 mg) were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), transferred to nitrocellulose membrane, and
probed with anti-NAG-1, PARP, cleaved caspase-3, or a–tubulin antibody. (B and C) Apoptosis in KB cells was determined by the TUNEL method and
FACS with AnnexinV-FITC/PI, as described in Fig. 3. Data are mean values obtained from three independent experiments and bars represent standard
deviations. The scale bar denotes 50 mm.
doi:10.1371/journal.pone.0034988.g004
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PLoS ONE | www.plosone.org 6 April 2012 | Volume 7 | Issue 4 | e34988Figure 5. Effect of suppression of NAG-1 expression on TA-induced apoptosis in KB cells. KB cells transfected with either the indicated
NAG-1 siRNA or negative control siRNA were treated with or without 30 mM TA for 24 h. Apoptosis was analyzed by the TUNEL assay and by FACS
with AnnexinV-FITC/PI. (A) Western Blot. Equal amounts of cell lysates (30 mg) were resolved by SDS-PAGE, transferred to nitrocellulose membrane,
and probed with anti- NAG-1, PARP, cleaved caspase-3, oraa–tubulin. (B and C) Apoptosis in KB cells was determined by the TUNEL method and FACS
with AnnexinV-FITC/PI, as described in Fig. 3. Data are mean values obtained from three independent experiments and bars represent standard
deviations. The scale bar denotes 50 mm.
doi:10.1371/journal.pone.0034988.g005
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proteins such as vascular endothelial growth factor (VEGF),
VEGFR1, survivin, cyclin D1, and bcl-2, and these responses
contribute to their anticancer activity [31]. Recently, Kim et al.
showed that COX-1 and COX-2 proteins were not changed by
TA and that TA induced cell growth inhibition occurred in a
COX-independent manner in KB HNSCC cells [32].
Despite these advancements in knowledge, the molecular
mechanism of TA on antitumorigenesis in HNSCC is not clear.
It is likely that multiple mechanisms are operative. The effects of
TA on the growth of KB human cancer cells and the mechanism
underlying these effects were presently investigated.
In this study, we demonstrated that NSAIDs induce NAG-1
expression and apoptosis in HNSCC cells, and that TA is the most
potent NSAID of those tested. Although the induction of apoptosis
Figure 6. Effect of TA on antitumor effect and in vivo expression of NAG-1 in BALB/c nu/nu mice. (A) BALB/c nu/nu mice were randomly
divided into two equal groups (control and 25 mg/kg) after injection of KB cells. After tumor formation (around 100 mm in diameter), treatment was
started with intraperitoneal injection of either TA (25 mg/kg) daily (treatment groups) or an equal volume of saline alone (control group). Animals
were killed and tumors were collected and weighed 17 days after implantation. (B) Graph of the volume and weight of tumors. (C) TUNEL staining in
control and treatment groups. The scale bar denotes 50 mm. (D) NAG-1 expression in implanted KB tumors. The induction of NAG-1 by TA is
compared to each control.
doi:10.1371/journal.pone.0034988.g006
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[10,11,33,34,35], the specific NSAID that causes maximal
induction of NAG-1 expression depends on the type of cancer
cell. For example, sulindac sulfide is the most potent NAG-1
inducer in colorectal cancer and indomethacin is the most potent
in sinonasal cancer [5,10,36] These differences are probably
related to the complex regulation of NAG-1 expression, which
involves both transcriptional and posttranscriptional mechanisms.
Furthermore, its expression seems to involve cis- and trans-acting
promoter elements, various transcription factors, and several
antitumorigenic substances [37]. NAG-1 is also a downstream
target of the diverse p53, ERG-1 and AKT/GSK-3 tumor
suppressing pathways [12,13,14,38,39,40,41]. Thus, the mecha-
nism of NAG-1 regulation depends on cell type and the mode of
induction. Further studies on the induction of NAG-1 by TA in
HNSCC cells are necessary.
The present data demonstrate that NAG-1 is one of the key
regulators for TA-induced apoptosis. TA inhibited the growth of
KB cells (Fig. 1). A higher concentration of TA (100 mM) resulted
in more than 70% cell death, with cells becoming detached and
rounded-up within 24 h after treatment.
In addition, TA induced apoptosis as evidenced by the
increased sub-G1 population, nucleosomal fragmentation (data
not shown), and cleaved PARP (Fig. 2), suggesting that apoptosis
contributes to the inhibitory effects of TA on the viability of KB
cells. These results agree with previous reports that TA induces
PARP cleavage in colorectal cancer cells [30] and pancreatic
cancer cells [28].
Mitochondrial damage manifests as an initial hyperpolarization,
followed by a loss of the mitochondrial membrane potential and
the release of proteins from the mitochondrial intermembrane
space, such as cytochrome c. Direct and indirect perturbation of
the mitochondria can activate the apoptotic pathway. TA
significantly induced the loss of MMP (Fig. 3), suggesting that
mitochondrial damage is involved in TA-induced apoptosis.
NAG-1 was induced by TA in a dose- and time-dependent
manner (Fig. 2), and overexpression of NAG-1 enhanced the
apoptotic effect of TA (Fig. 4). Moreover, siRNA-mediated
knockdown of NAG-1 attenuated TA-induced apoptosis (Fig. 5),
suggesting that NAG-1 expression is closely associated with
apoptosis.
The in vivo anticarcinogenic activity of TA was investigated in
athymic nude mice bearing KB cells as xenografts. At a dose of
25 mg/kg/day, TA significantly inhibited tumor growth and
weight and increased TUNEL positive staining cells (apoptosis) in
tumor sections from treated versus control animals. This was
accompanied by increased NAG-1 staining in tumors from treated
mice (Fig. 6). Clinical studies with TA for chronic treatment of
rheumatoid arthritis has used doses of TA as high as 10 mg/kg/
day, which is only 2.5-fold lower than the dose required for
inhibition of HNSCC tumor growth in a xenograft mouse model.
These results demonstrate that TA is a highly effective anticancer
agent in both in vitro and in vivo models of HNSCC, and
complements previous results [29,31,32]. The mechanism of
action of TA as a tumor growth inhibitor is due, in part, to
induction of NAG-1 and NAG-1-related genes.
The linkage between NAG-1 induction and TA revealed in this
study provides a new molecular mechanism that may contribute to
the anti-tumorigenic activities of TA in HNSCC.
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